Clinical Applications of Nanosized Drug-Delivery Systems in Lung Cancer Imaging and Therapy.

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2020-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2020031657
Merve Karpuz, Mine Silindir-Gunay, Asuman Yekta Ozer
{"title":"Clinical Applications of Nanosized Drug-Delivery Systems in Lung Cancer Imaging and Therapy.","authors":"Merve Karpuz,&nbsp;Mine Silindir-Gunay,&nbsp;Asuman Yekta Ozer","doi":"10.1615/CritRevTherDrugCarrierSyst.2020031657","DOIUrl":null,"url":null,"abstract":"<p><p>Globally, lung cancer is one of the most frequently diagnosed and deadliest types of cancer. Lung cancer imaging can be performed using both invasive and noninvasive techniques, including magnetic resonance, positron emission tomography, single photon emission computed tomography, chest radiography, and computed tomography. But nonspecific contrast agents and radiopharmaceuticals are insufficient for early and specific diagnoses and imaging. In the case of lung cancer therapy, conventional therapeutic agents and radiotherapy may cause severe and systemic adverse and toxic effects and fail to eradicate all tumor tissue. Therefore, formulation of novel, targeted, and specific agents is critically important to overcome these challenges. In this review, we summarize lung cancer classification, current methods for lung cancer imaging and therapy, and future options containing nanosized systems for lung cancer imaging and/or therapy.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020031657","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 4

Abstract

Globally, lung cancer is one of the most frequently diagnosed and deadliest types of cancer. Lung cancer imaging can be performed using both invasive and noninvasive techniques, including magnetic resonance, positron emission tomography, single photon emission computed tomography, chest radiography, and computed tomography. But nonspecific contrast agents and radiopharmaceuticals are insufficient for early and specific diagnoses and imaging. In the case of lung cancer therapy, conventional therapeutic agents and radiotherapy may cause severe and systemic adverse and toxic effects and fail to eradicate all tumor tissue. Therefore, formulation of novel, targeted, and specific agents is critically important to overcome these challenges. In this review, we summarize lung cancer classification, current methods for lung cancer imaging and therapy, and future options containing nanosized systems for lung cancer imaging and/or therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纳米给药系统在肺癌成像和治疗中的临床应用。
在全球范围内,肺癌是最常见和最致命的癌症类型之一。肺癌成像可以使用侵入性和非侵入性技术进行,包括磁共振、正电子发射断层扫描、单光子发射计算机断层扫描、胸部x线摄影和计算机断层扫描。但非特异性造影剂和放射性药物不足以进行早期和特异性诊断和成像。在肺癌治疗中,传统的治疗药物和放疗可能会引起严重的全身不良和毒性作用,并不能根除所有的肿瘤组织。因此,新型的、有针对性的、特异的制剂对于克服这些挑战至关重要。在这篇综述中,我们总结了肺癌的分类,目前肺癌成像和治疗的方法,以及未来肺癌成像和/或治疗的纳米系统的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.50
自引率
18.50%
发文量
27
审稿时长
>12 weeks
期刊介绍: Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
期刊最新文献
Enhancing Microemulsion based Therapeutic Drug Delivery: Exploring Surfactants, Co-surfactants, and Quality by Design Strategies within Pseudo-ternary Phase Diagrams NOVEL DRUG DELIVERY TOOLS FOR BETTER PERMEATION AND SKIN CANCER TREATMENT Nanobiocatalysts and Nanozymes: Enzyme-Inspired Nanomaterials for Industrial and Biomedical Applications Navigating the Challenges of 3D Printing Personalized Medicine in Space Explorations: A Comprehensive Review From Conventional to Novel Drug Delivery Systems for Meloxicam: A Systematic Review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1